Seres Therapeutics Announces Appointment Of Wael Hashad As Chief Commercial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics company, announced today that it has appointed Wael Hashad as Chief Commercial Officer and Executive Vice President.

In this newly created role, Hashad will be responsible for all activities related to the anticipated commercialization of the company's products in development, including SER-109, which is currently in a Phase 2 clinical study for recurring Clostridium difficile infection (CDI). He will report to Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of Seres.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.